Angioedema: Some “new” thoughts regarding idiopathic angioedema

Urticaria and Angioedema

Volumn , Issue , 2004, Pages 421-440

  Beltrani, Vincent S ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645423783     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Rook A. The Historical Background. In: Warin RP, ed. Urticaria. London: W.B. Saunders Company Ltd., 1974:5.
2. Larsen FS. Epidemiology and socioeconomic impact of allergic skin diseases. In: Leung DYM, Greaves MW. eds. Allergic Skin Disease. New York: Marcel Dekker. 2000:7
3. Kerel FA. SOler NA. Mast cell-mediated cutaneous disease. In: Charlesworth EN, ed. Cutaneous Allergy. Cambridge. UK: Blackwell Science. 1996:262.
4. Soter NA, Wasserman SI. IgE-dependent urticaria and angioedema - 19. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine. 3rd ed. McGraw-Hill, 1987: 1283.
5. Champion RH. Roberts SOB, Carpenter RG, Rogers JH. Urticaria and angioedema: a review of 554 patients. Br J Dermatol 1969; 81:588.
6. Warin RP, Champion RH. Types and incidence of urticaria. In: Warin RP, ed. Urticaria-Major Problems in Dermatology. Vol. 1. London: WB Saunders, 1974: 12
7. Hedner T, Samuelsson O, Lunde H, et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitor. Br Med J 1992; 304 941-946
8. Frigas E, Nzeako UC. Angioedema-pathogenesis, differential diagnosis and treatment. Clin Rev Allergy Immunol 2002; 23:217-231.
9. Agostini A, Acardi M. Drug induced angioedema without urticaria. Drug Saf 2001; 24:599-606
10. Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 89:542-550.
11. Carugati A, Pappalardo E, Zingale LC, Cicardi M. CI-inhibitor deficiency and angioedema. Mol Immunol 2001; 38:161-173.
12. Ebo DG, Stevens WJ., Hereditary angioedema: Review of the literature. Acta Clin Belg 2000; 55:22-29.
13. Molinaro G, Cugno M, Perez M, et al. ACE inhibitor-associated angioedema is characterized by a slower degradation of desargininie(9)-bradykinin. J Pharmacol Exp Ther 2002; 303:232-237
14. Tom B, Dendorfer A, deVries R, et al. Bradykinin potentiation by ACE inhibitors: a maller of metabolism. Br J Pharmacol 2002; 137:276-284.
15. Higashi N, Taniguchi M, Mita H, et al. Aspirin-induced urticaria and angioedema, but not bronchoconstriction, associated with cysteinyl leukotriene overproduction in 2 patients with asthma. J Allergy C1in Immunol 2002; 110:666-667.
16. Reilly DM, Parslew R, Sharpe GR, et al. Inflammatory mediators in normal. sensitive and diseased skin types. Acta Derm Venereol 2000; 80: 171-174.
17. Roitt I, Brostofl- J, Male D. Hypersensitivity-type I. In: Roitt L Male D. Brostoff J, eds. Immunology-Fifth Edition. London: CV Mosby, 1998: 309-310.
18. Koro O, Furutani K, Hide M, et al. Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999; 103: 663-670.
19. Hamann CP, Sullivan KM. Natural rubber latex Hypersensitivities. In: Charlesworth EN, ed. Cutaneous Allergy. Cambridge, UK: Blackwell Science, 1996:171-172
20. Sanches-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol: 2000; 84: 101-106
21. Frigas E, Nzeako UC. Angioedema: pathogenesis, differential diagnosis, and treatment. Clin Rev Allergy Immunol 2002; 23:217-231.
22. Cohen EG, Soliman AM. Changing trends in angioedema. Ann Otol Rhinol Laryngol 2001; 110:701-706.
23. Agah R. Bandi V. Gunturpalli KK. Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 1999; 23: 793-796
24. Agostini A, Cicardi M, Cugno M, et al. Angioedema due to ACE inhibitors. 1ml11unopharmacology 1999: 15:21-25.
25. Byrne TJ, Douglas DO., Landis ME, et al. Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors. Mayo Clin Proc 2000; 75: 1201-1204
26. Vleming W, vanAmsterdam JG, Stricker BH, deWildt OJ. Ace inhibitor-induced AE. Incidence, prevention and management. Drug Safety 1998; 18:171-188
27. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor AE. Ann Pharmacother 2000: 34:536-538.
28. Eck SL, Morse JH, Janssen DA, et al. Hereditaary angioedema. Am J Gastroenterol 1993; 88:436-439.
29. Heymann WR. Acquired angioneurotic edema. J Am Acad Dermatol 1997; 36:611-615
30. Lawlor EF. The Physical Urticaria. In: Leung DYM, Greaves MW, eds. Allergic Skin Disease. New York: Marcel Dekker, 2000:195.
31. Kozel MA, Mekkes JR., Bossuyt PMM., Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001: 45387-391.
32. Simons FER. Antihistamines. In: Middleton E, Reed CE, Ellis EF, et al., eds. Allergy: Principles & Practice. 5th ed. St. Louis: CV Mosby, 1998:612-637.
33. Mansfield LE, Smith JA, Nelson HS. Greater inhibition of dermographia with HI and H2 antagonists. Ann Allergy 1983; 50:264-270.
34. Bleehen SS, Thomas SE, Greaves MW, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-center randomized double-blind study. Br J Dermatol 1987; 117:81-91.
35. Sim TC, Grant JA. H I-receptor Antagonists in chronic urticaria. In: Simons FER, ed. Histamine and H I-Receptor Antagonists in Allergic Disease. New York: Marcel Dekker, 1996:277.
36. Gupta MA, Gupta AK., Ellis CN. Antidepressant drugs in dermatology. Arch Dermatol 1987; 113:647-652.
37. Green SL., Reed CE, Schroeter AL. Double-blind cross-over study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985: 12:669-675.
38. Stranaland BE. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy 1ml1lunol 2002: 23:233-241.
39. Kennard CD, Ellis CN. Pharmacologic therapy for urticaria. J Am Acad Dermatol 1991; 125:176-189
40. Heilborn H, Hjemdahl HH, Daleskog M, et al. Comparison of subcutaneous injection and high-dose inhalation of epinephrine-implications for selftreatmenl. J Allergy C1in lmmunol 1986; 78: 1174-1179.
41. Avila PC, Kishiyama JL, Adelman DC. Pharmacologic approaches. In: Zweiman B, Schwartz LB, eds. Inflammatory Mechanisms in Allergic Diseases. New York: Marcel Dekker, 2002:481.
42. Onnen JM, Israel E, O’ Byrne PM Treatment of asthma with drugs modifying the leucotriene pathway. N Engl J Med 1999; 340: 197-206
43. Spector S, Tan RA. Antileueotrienes in chronic urticaria. J Allergy C1in [mmunol 1998; 102:572.
44. Ellis M H, Successful treatment of chronic urticaria with leucotriene antagonists. J Allergy Clin IIll1llunoi 1998; 102:786-787
45. Chiu TJ, Warren MS. Zafirlukast in the treatment of chronic urticaria-a case series. J Allergy C1in Immunol 1998; 101 (suppl):S155.
46. Norris JG, Sullivan TJ. Leucotrienes and cytokines in steroid dependent chronic urticaria. J Allergy Clin Immunol 1998; (suppl):S 128
47. Asero R. Leucotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma lmll1unol 2000; 85: 156-157.
48. Perez C., Sanches-Borges M, Capriles E. Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 2001; 1060-1061.
49. Pacor ML, DiLorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonists in chronic urticaria. Clin Exp Allergy 2001; 31:1607-1614.
50. Barnes PJ, Pedersen S, Busse WW Effects and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157:S1-S53.